Bulk Estrogenic Female Hormone Anti Estrogen Steroids Powder Ethynyl Estradiol 57-63-6
Product name:Ethynyl estradiol
Appearance:Fine white powder
Mol File: 57-63-6.mol
Melting Point: 182-183 ° C(lit. )
Boiling Point: 457.2 ° C at 760 mmHg
Flash Point: 211.2 ° C
Deliver time:About 1-3 days
Ethinylestradiol is a man-made form of the naturally occurring female hormone called oestrogen. It is prescribed to treat period (menstrual) problems, and also to help ease menopausal symptoms. It is usually prescribed alongside another female hormone called a progestogen.
Ethinyl estradiol also sometimes written as ethinylestradiol, ethynyl estradiol, or ethinyl? Stradiol, is a derivative of 17 -estradiol (E2), the major endogenous estrogen in humans. EE is an orally bioactive estrogen used in many formulations of combined oral contraceptive pills. It is one of the most commonly used medications for this purpose.
Estinyl was a preparation of EE alone that was used for the management of menopausal symptoms and female hypogonadism.
EE is released into the environment as a xenoestrogen from the urine and feces of people who take it as a medication.
When estrogen is prescribed for a woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Short-term cyclic use for treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.
Attempts to discontinue or taper medication should be made at 3- to 6-month intervals. The usual dosage range is 1 to 5 mg injected every 3 to 4 weeks.
For treatment of female hypoestrogenism due to hypogonadism 1.5 to 2 mg injected at monthly intervals.
Ethynyl Estradiol Medical uses
As Estinyl, EE was formerly used for hormone replacement therapy in menopause and the treatment of female hypogonadism, loss of menstruation, dysmenorrhea, acne, prostate cancer, and breast cancer. However, in more recent times, EE is mainly used in COCs. In contraception, due to concerns of unopposed estrogen action and the possible increased risk of endometrial cancer that accompanies this, EE is formulated in combination with progestins. EE is little used in menopausal hormone replacement therapy. EE has been used at very high dosages (1–2 mg/day) in the treatment of prostate cancer.
Ethynyl Estradiol Side effects
Side effects of EE are the same as for other estrogens and include breast tenderness, headache, fluid retention (bloating), nausea, dizziness, and weight gain. The estrogen component of oral contraceptives, which is almost always EE, can cause breast tenderness and fullness
The high doses of EE that were used in early COCs were associated with a significantly increased risk of endometrial cancer in certain preparations, for instance those containing the progestogen dimethisterone. Unopposed estrogens like EE have carcinogenic effects in the endometrium and progestogens protect against these effects, but dimethisterone is a relatively weak progestogen and was unable to adequately antagonize the endometrial carcinogenic effects of EE, in turn resulting in the increased risk of endometrial cancer. COCs containing dimethisterone have since been discontinued (with more potent progestogens used instead) and doses of EE in COCs in general have been dramatically reduced, abrogating the risk. In turn, most studies of modern COCs have found a decreased risk of endometrial cancer.
1 Testosterone Enanthate CAS: 315-37-7
2 Testosterone Acetate CAS: 1045-69-8
3 Testosterone Propionate CAS: 57-85-2
4 Testosterone Cypionate CAS: 58-20-8
5 Testosterone Phenylpropionate CAS: 1255-49-8
6 Testosterone Isocaproate CAS: 15262-86-9
7 Testosterone Decanoate CAS: 5721-91-5
8 Testosterone Undecanoate CAS: 5949-44-0
9 Sustanon 250
11 Turinabol CAS: 855-19-6
12 Oral Turinabol CAS: 2446-23-3
13 Stanolone CAS: 521-18-6
14 Nandrolone Decanoate (DECA) CAS: 360-70-3
15 Nandrolone Cypionate CAS: 601-63-8
16 Nandrolone Phenypropionate (NPP) CAS: 62-90-8
17 Boldenone Acetate CAS :2363-59-9
18 Boldenone Undecylenate (Equipoise) CAS: 13103-34-9
19 Drostanolone Propionate (Masteron) CAS: 521-12-0
20 Drostanolone Enanthate CAS: 472-61-1
21 Methenolone Acetate (Primobolan) CAS: 434-05-9
22 Methenolone Enanthate CAS: 303-42-4
23 Trenbolone Acetate CAS: 10161-34-9
24 Trenbolone Enanthate
25 Trenbolone Hexahydrobenzyl Carbonate CAS: 23454-33-3
26 Epiandrosterone CAS: 481-29-8
27 Anavar CAS: 53-39-4
28 Anadrol CAS: 434-07-1
29 Winstrol CAS: 10418-03-8
30 Dianabol CAS: 72-63-9
31 Superdrol CAS: 3381-88-2
32 Tamoxifen Citrate (Nolvadex) CAS: 54965-24-1
33 Clomiphene Citrate (Clomid) CAS: 50-41-9
34 Toremifene Citrate (Fareston) CAS: 89778-27-8
35 Femara CAS: 112809-51-5
36 Aromasin CAS: 107868-30-4
37 Proviron CAS: 1424-00-6
38 Arimidex CAS: 120511-73-1